Mechanism Diligence
Basic video pending

Medicine reading guide

Pembrolizumab (Keytruda)

Intravenous Keytruda alone for unresectable or metastatic melanoma in adults. Educational draft. Independent clinical review pending. Not personal medical advice.

How it works

Some cancers use a signal that tells immune cells to slow down. Pembrolizumab blocks the PD-1 receptor on T cells so that signal cannot act through it. This can help the immune system respond to the cancer. It can also lead to inflammation in healthy organs, during treatment or after it ends.

Keytruda prescribing information · §§5.1 and 12.1

Audience explanation sources

Editorial source review completed November 11, 2026. Independent clinical review pending. Audience versions explain the same scoped medicine; they are not separate treatment plans.

Educational draft. Independent clinical review pending.

Written explanation

Adults receiving single-agent intravenous Keytruda for unresectable or metastatic melanoma. Excludes postoperative treatment, other cancers, combinations, children and subcutaneous Keytruda Qlex.

Existing authored material. Source-check record: 2026-10-12. Independent clinical review pending.

Checkpoint: PD-1 signaling can restrain T-cell immune responses when it binds PD-L1 or PD-L2.

DailyMed / NLM

Blockade: pembrolizumab binds PD-1 and prevents those interactions, releasing that restraint. Healthy organs can also develop immune inflammation.

DailyMed / NLM

Which use does this guide cover?

This guide covers Keytruda given alone by infusion for melanoma that cannot be removed by surgery or has spread to other parts of the body.

DailyMed / NLM

How does it work?

T cells are immune cells that can attack cancer. A receiver called PD-1 can tell them to ease off. Pembrolizumab blocks that receiver, helping release this brake on the immune response. The same change can also let the immune system attack healthy organs.

DailyMed / NLM

How is it given?

A trained professional gives it by intravenous infusion in a medical facility.

MedlinePlus / NLM

What side effects might occur?

Fatigue, nausea, decreased appetite and muscle or joint pain. Report persistent symptoms.

MedlinePlus / NLM

Which symptoms need immediate contact?

Call your cancer team immediately for new breathlessness, chest pain, severe diarrhea, bloody stools, yellow skin or severe rash.

MedlinePlus / NLM

Can immune side effects start after treatment ends?

Yes. Immune-related injury can appear after discontinuation; continue reporting new symptoms.

DailyMed / NLM

Why are blood tests needed?

The team monitors liver, kidney and thyroid function for treatment-related problems.

DailyMed / NLM

What should I report during infusion?

Immediately alert staff to chills, rash, dizziness or breathing difficulty.

MedlinePlus / NLM

Which medical history matters?

Mention autoimmune disease, organ or donor-stem-cell transplants, lung disease and prior chest radiation.

MedlinePlus / NLM

Should I report other treatments?

Give the team your complete medicine and supplement list before starting or changing treatment.

MedlinePlus / NLM

What about pregnancy or breastfeeding?

Keytruda can harm a fetus. If you can become pregnant, use effective contraception during treatment and for four months after the last dose. Do not breastfeed during treatment or for four months after the last dose. Discuss this plan with your cancer team before treatment.

MedlinePlus / NLM

Keytruda prescribing information · 5.5 and 8.1–8.3

Sources for this written explanation